Attaining and sustaining remission of predominant negative symptoms

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 60-64

  Levine, Stephen Z ^a   Leucht, Stefan ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic medication; Clinical trial; Negative symptoms; Remission; Schizophrenia

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOPHRENIA; SURVIVAL; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; SCHIZOPHRENIA; SULPIRIDE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871932147     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.11.010     Document Type: Article

References (37)

1. Addington J., Addington D. Symptom remission in first episode patients. Schizophr. Res. 2008, 106(2-3):281-285.
2. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):225-230.
3. Andreasen N.C. Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City.
4. Andreasen N.C. Scale for the Assessment of Positive Symptoms 1983, University of Iowa, Iowa City.
5. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
6. Angermeyer M.C., Kuhn L., Goldstein J.M. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr. Bull. 1990, 16(2):293-307.
7. Beitinger R., Lin J., Kissling W., Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(7):1643-1651.
8. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163(3):418-425.
9. Danion J.M., Rein W., Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiatry 1999, 156(4):610-616.
10. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89(1-3):129-139.
11. Forbes C., Blanchard J.J., Bennett M., Horan W.P., Kring A., Gur R. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr. Res. 2010, 124(1-3):36-42.
12. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007, 12(10):904-922.
13. Hafner H. Onset and early course as determinants of the further course of schizophrenia. Acta Psychiatr. Scand. Suppl. 2000, 407:44-48.
14. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32(2):250-258.
15. Horan W.P., Kring A.M., Gur R.E., Reise S.P., Blanchard J.J. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr. Res. 2011, 132(2-3):140-145.
16. Kane J.M. An evidence-based strategy for remission in schizophrenia. J. Clin. Psychiatry 2008, 69(Suppl. 3):25-30.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
18. Kirkpatrick B., Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr. Bull. 2006, 32(2):246-249.
19. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
20. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A. The brief negative symptom scale: psychometric properties. Schizophr. Bull. 2011, 37(2):300-305.
21. Leucht S., Pitschel-Walz G., Engel R.R., Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002, 159(2):180-190.
22. Leucht S., Beitinger R., Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl.) 2007, 194(4):453-461.
23. Leucht S., Shamsi S.A., Busch R., Kissling W., Kane J.M. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr. Res. 2008, 101(1-3):312-319.
24. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
25. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. Suppl. 2009, 438:7-14.
26. Leucht S., Kissling W., Engel R.R., Davis J.M. Are new drugs for schizophrenia better than old ones? Authors' reply. Lancet 2009, 373(9671):1249-1250.
27. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000, 401:3-38.
28. Levine S.Z., Leucht S. Delayed- and Early- Onset Hypotheses of Antipsychotic Drug Action in the Negative Symptoms of Schizophrenia. European Neuropsychopharmacology 2012, 22:812-817.
29. Levine S.Z., Rabinowitz J., Ascher-Svanum H., Faries D.E., Lawson A.H. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr. Res. 2011, 133:42-46.
30. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50(11):884-897.
31. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
32. Loo H., Poirier-Littre M.F., Theron M., Rein W., Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry 1997, 170:18-22.
33. Marder S.R., Daniel D.G., Alphs L., Awad A.G., Keefe R.S. Methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37(2):250-254.
34. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17:1206-1227.
35. Rabinowitz J., Levine S.Z., Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr. Res. 2006, 88(1-3):96-101.
36. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137(1-3):147-150.
37. Storosum J.G., Elferink A.J., Van Zwieten B.J., Van Strik R., Hoogendijk W.J., Broekmans A.W. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?. Schizophr. Bull. 2002, 28(2):193-201.